| Bioactivity | Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of drugs to the human CNS[1][2]. | ||||||||||||
| In Vivo | Regadenoson (0.1, 0.175, 0.25, 0.5, 1.0, 2.5, 5 µg/kg; p.i.v.; single) increases coronary blood flow (CBF) and decreases in mean coronary resistance in a dose-dependent manner, in awake dogs[1].Regadenoson (2.5 µg/kg; p.i.v.; single in 30 s) increases blood flow of coronary in awake dogs[1].Regadenoson (0.5 µg/kg; i.v.; single; 60 or 90 min after Temozolomide administration) promotes Temozolomide delivery to CNS of rats[2]. Animal Model: | ||||||||||||
| Name | Regadenoson | ||||||||||||
| CAS | 313348-27-5 | ||||||||||||
| Formula | C15H18N8O5 | ||||||||||||
| Molar Mass | 390.35 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Trochu JN, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol. 2003 Jan;41(1):132-9. [2]. Jackson S, et al. The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neurooncol. 2016 Feb;126(3):433-9. |
Regadenoson
CAS: 313348-27-5 F: C15H18N8O5 W: 390.35
Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow,
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.